title: Adverse events among COPD patients treated with long-acting anticholinergics and β2-agonists in an outpatient respiratory clinic.
abstract: BACKGROUND
  Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. Most patients with COPD receive long-term treatment with long-acting anticholinergics (LAAC) and/or long-acting β2-agonists (LABA). Adverse events (AEs) are also likely during long-term treatment with these medications.
  
  
  OBJECTIVE
  To evaluate the prevalence of AEs in COPD patients on LAAC and LABA in a real-world setting.
  
  
  METHODS
  We conducted a cross-sectional study of patients enrolled in the Registre de Données en Santé Pulmonaire (RESP) database, which records information on Canadian patients with asthma or COPD. COPD Patients completed a questionnaire about AEs that may be associated with LAAC and/or LABA. The prevalence of AEs and the corresponding 95% CI were calculated for three groups of patients (LAAC + LABA, LAAC alone, and LABA alone).
  
  
  RESULTS
  Most patients with COPD (n = 154) were current or ex-smokers. Over 50% of patients were overweight or obese, and had an annual family income of less or equal to $42,000. Dry mouth (55.2%, 40%, and 43.5%) and dry throat (33.6%, 26.7%, and 34.8%) occurred most of the time or always in the LAAC + LABA, LAAC, and LABA groups, respectively. Headache was reported by 17.4% of patients in the LABA group, but less than 11.2% in the other groups.
  
  
  CONCLUSIONS
  AEs reported in this study deserve clinical attention because they may negatively affect quality of life and treatment adherence of COPD patients.
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montreal, H3C 3J7, Canada.
authors.forename: Claudie
authors.initials: C
authors.lastname: Rodrigue
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montreal, H3C 3J7, Canada; Pharmacy Department, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, J1H 5N4, Canada; Centre de Recherche, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, J1H 5N4, Canada; Faculty of Medicine, Université de Sherbrooke, Sherbrooke, J1H 5N4, Canada.
authors.forename: Marie-France
authors.initials: MF
authors.lastname: Beauchesne
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montreal, H3C 3J7, Canada.
authors.forename: François
authors.initials: F
authors.lastname: Savaria
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montreal, H3C 3J7, Canada.
authors.forename: Amélie
authors.initials: A
authors.lastname: Forget
authors.affiliation: Faculty of Medicine, Université de Montréal, Montreal, H3C 3J7, Canada; Research Center, Hôpital du Sacré-Coeur de Montréal, Montreal, H4J 1C5, Canada.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lemière
authors.affiliation: Centre de Recherche, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, J1H 5N4, Canada; Faculty of Medicine, Université de Sherbrooke, Sherbrooke, J1H 5N4, Canada.
authors.forename: Pierre
authors.initials: P
authors.lastname: Larivée
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montreal, H3C 3J7, Canada; Research Center, Hôpital du Sacré-Coeur de Montréal, Montreal, H4J 1C5, Canada. Electronic address: lucie.blais@umontreal.ca.
authors.forename: Lucie
authors.initials: L
authors.lastname: Blais
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D000069451:Long Term Adverse Effects / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011788:Quality of Life
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D018680:Cholinergic Antagonists
keywords: Adverse events; COPD; Long-acting bronchodilators; Obstructive lung disease